Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules

[1]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. , 2010, Arthritis and rheumatism.

[2]  J. Zimmer,et al.  Inefficient protection of human TAP‐deficient fibroblasts from autologous NK cell‐mediated lysis by cytokines inducing HLA class I expression , 1999, European journal of immunology.

[3]  A. Plebani,et al.  HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. , 1999, The Journal of clinical investigation.

[4]  K. Tadokoro,et al.  Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. , 1999, The Journal of clinical investigation.

[5]  J. Zimmer,et al.  Activity and Phenotype of Natural Killer Cells in Peptide Transporter (TAP)-deficient Patients (Type I Bare Lymphocyte Syndrome) , 1998, The Journal of experimental medicine.

[6]  V. Cerundolo,et al.  A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. , 1997, Immunology letters.

[7]  M. Colonna.  Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors , 1997, Immunological reviews.

[8]  L. Notarangelo,et al.  Defective expression of HLA class I and CD1a molecules in boy with Marfan-like phenotype and deep skin ulcers. , 1996, Journal of the American Academy of Dermatology.

[9]  J. Orange,et al.  Characterization of early IL-12, IFN-alphabeta, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. , 1996, Journal of immunology.

[10]  L. Lanier,et al.  Inhibitory MHC class I receptors on NK cells and T cells. , 1996, Immunology today.

[11]  D. Roseeuw,et al.  Unusual clinical manifestation of a disfiguring necrobiotic granulomatous disease. , 1995, Journal of the American Academy of Dermatology.

[12]  J. Yewdell,et al.  Assembly, Intracellular Localization, and Nucleotide Binding Properties of the Human Peptide Transporters TAP1 and TAP2 Expressed by Recombinant Vaccinia Viruses (*) , 1995, The Journal of Biological Chemistry.

[13]  R. Porter.  Nomenclature of Systemic Vasculitides: Proposal of an International Consensus Conference , 1995 .

[14]  G. Ferrara,et al.  NK3-specific natural killer cells are selectively inhibited by Bw4- positive HLA alleles with isoleucine 80 , 1994, The Journal of experimental medicine.

[15]  J. Salamero,et al.  Homozygous human TAP peptide transporter mutation in HLA class I deficiency. , 1994, Science.

[16]  R J Falk,et al.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.

[17]  K. Ohnishi,et al.  Differential regulation of formation of multinucleated giant cells from concanavalin A-stimulated human blood monocytes by IFN-gamma and IL-4. , 1993, Journal of immunology.

[18]  P. Cresswell,et al.  Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer , 1992, Nature.

[19]  Shinichi Watanabe,et al.  Immunohistochemical studies of major histocompatibility antigens in a case of the bare lymphocyte syndrome without immunodeficiency. , 1987, Journal of the American Academy of Dermatology.

[20]  A. D. Kornblut,et al.  Wegener's granulomatosis. , 1974, Otolaryngologic clinics of North America.

[21]  R. Hertz,et al.  WEGENER'S GRANULOMATOSIS. , 1963, The American journal of medicine.

[22]  J. L. Fahey,et al.  Wegener's granulomatosis. , 1954, The American journal of medicine.

[23]  K. Tadokoro,et al.  Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I). , 1999, Human immunology.

[24]  Patricia Woo,et al.  Oxford textbook of rheumatology , 1995 .

[25]  B. Haynes,et al.  Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. , 1983, Annals of internal medicine.